Pancreatic Cancer Research

ResearcherKobe University HospitalActive in the last 2 years

Hironobu Minami

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8630-9145; OpenAlex author ID A5089137663. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 10

  1. Triplet chemotherapy with Gemcitabine, Nab-paclitaxel, and S-1 achieves high response and conversion rates in advanced pancreatic cancer: A multicenter phase I… Last author DOI 10.1016/j.ejca.2026.117034↗
  2. Optimizing chemotherapy regimens and dosing for older patients with metastatic pancreatic cancer: insights from the Tokushukai real-world data project. Last author DOI 10.1186/s12885-026-15711-1↗
  3. Analysis of thromboembolism and prognosis in metastatic pancreatic cancer from the Tokushukai REAl‑world data project. Last author DOI 10.3892/mco.2024.2771↗
  4. Inflammation‑based prognostic markers of metastatic pancreatic cancer using real‑world data in Japan: The Tokushukai REAl‑world Data (TREAD) project. Last author DOI 10.3892/ol.2024.14269↗
  5. Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project. Last author DOI 10.3892/mco.2023.2694↗
  6. Phase 1 study of Gemcitabine/Nab-paclitaxel/S-1 in patients with unresectable pancreatic cancer (GeNeS1S trial). Last author DOI 10.1007/s00280-020-04174-1↗
  7. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancrea… Last author DOI 10.1007/s00280-016-3026-6↗
  8. Chemotherapy-induced Nausea and Vomiting in Patients with Hepatobiliary and Pancreatic Cancer Treated with Chemotherapy: A Prospective Observational Study by t… Co-author PMID 27069182↗
  9. Metabolomics evaluation of serum markers for cachexia and their intra-day variation in patients with advanced pancreatic cancer. Last author DOI 10.1371/journal.pone.0113259↗
  10. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Co-author DOI 10.1158/1055-9965.epi-12-1033↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rai Shimoyama · 4 shared papers, 2023–2026 · strength 0.86
  2. Hisateru Yasui · 2 shared papers, 2021–2026 · strength 0.36
  3. Hirochika Toyama · 2 shared papers, 2021–2026 · strength 0.36
  4. Sakue Masuda · 1 shared paper, 2026 · strength 0.28
  5. Yoshiaki Nagatani · 1 shared paper, 2026 · strength 0.24
  6. Satoshi Sai · 1 shared paper, 2021 · strength 0.11
  7. Yuzo Kodama · 1 shared paper, 2021 · strength 0.11
  8. Yutaka Fujiwara · 2 shared papers, 2013–2014 · strength 0.07
  9. Takeshi Azuma · 2 shared papers, 2013–2014 · strength 0.07
  10. Takashi Kobayashi · 2 shared papers, 2013–2014 · strength 0.07
  11. Masaru Yoshida · 2 shared papers, 2013–2014 · strength 0.07
  12. Shinichi Ohkawa · 1 shared paper, 2016 · strength 0.06
  13. Mototsugu Shimokawa · 1 shared paper, 2016 · strength 0.06
  14. Hidetoshi Nitta · 1 shared paper, 2016 · strength 0.06
  15. Go Wakabayashi · 1 shared paper, 2016 · strength 0.06
  16. Junji Furuse · 1 shared paper, 2016 · strength 0.06
  17. Hideo Baba · 1 shared paper, 2016 · strength 0.06
  18. Kazuhide Yamamoto · 1 shared paper, 2016 · strength 0.06
  19. Meiko Nishimura · 1 shared paper, 2016 · strength 0.05
  20. Akihito Tsuji · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.